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Abstract
Aims: To assess insulin therapy, macronutrient intake and glycaemia in professional
cyclists with type 1 diabetes (T1D) over a 5-day Union Cycliste Internationale road-cycle
race.
Material and methods: In this prospective observational study, seven professional
cyclists with T1D (age 28 ± 4 years, body mass index 20.9 ± 0.9 kg/m2, glycated
haemoglobin concentration 56 ± 7 mmol/mol [7.3% ± 0.6%]) were monitored during
a five-stage professional road cycling race. Real-time continuous glucose monitoring
(rtCGM) data, smart insulin pen dose data and macronutrient intake were assessed
by means of repeated-measure one-way ANOVA and post hoc testing. Associations
between exercise physiological markers and rtCGM data, insulin doses and macronu-
trient intake were assessed via linear regression modelling (P ≤ 0.05).
Results: Bolus insulin dose was significantly reduced over the 5-day period (P = 0.03),
while carbohydrate intake (P = 0.24) and basal insulin doses remained unchanged
(P = 0.64). A higher mean previous-day race intensity was associated with a lower
mean sensor glucose level (P = 0.03), less time above range level 2 (>13.9 mmol/L
[250 mg/dL]; P = 0.05) and lower doses of bolus insulin (P = 0.04) on the subsequent
day. No significant associations were found for any other glycaemic range and
glycaemic variability (P > 0.05).
Conclusions: This is the first study to demonstrate the influence of previous-day race
intensity on subsequent bolus insulin dose requirements in professional cyclists with
T1D. These data may help inform therapeutic strategies to ensure safe exercise
performance.
1 | INTRODUCTION
The positive effects of physical activity and exercise have been
described in healthy1 and chronically ill people,2 detailing improve-
ments in cardiac and pulmonary diseases, cancer, depression and
metabolic-related disorders.2 In people with type 1 diabetes (T1D),3,4
the benefits of regular physical activity and exercise on glucose
metabolism, therapy management and comorbidities have led to the
inclusion of regular exercise in the treatment plan of diabetes.5 Never-
theless, only approximately 45% of all individuals with T1D achieve
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current physical activity and exercise recommendations,6,7 the main
reason for which is fear of losing glycaemic control.8 In recreationally
active people with T1D, insulin therapy9–11 as well as carbohydrate
intake12,13 must be tightly managed to minimize fluctuations in glu-
cose both below14 and above15 the target range. Furthermore, the risk
of exercise-related dysglycaemia persists for many hours subsequent
to its performance as a result of relative hyper- or hypoinsulinaemia,
accompanied by increased levels of insulin-independent glucose trans-
porter type 4 (GLUT-4).5 Therefore, it is recommended that individ-
uals with T1D make adaptations to their basal insulin dose/rate16,17
and/or consume a bedtime carbohydrate-rich snack without bolus
insulin administration after late afternoon exercise sessions.18
The majority of research pertinent to T1D and exercise has been
conducted in recreationally active people,19 whilst limited evidence
exists in athletes.20 Notably, the physiological characteristics of pro-
fessional athletes clearly differ from those of recreationally active
people, which is specifically observed in cardiopulmonary21 and meta-
bolic responses22 to exercise. A recent report assessing real-time con-
tinuous glucose monitoring (rtCGM) sensor glucose responses in a
group of professional cyclists with T1D, evidenced a progressive
increase in the amount of time spent in hypoglycaemia over 7 days of
road-cycle racing.23 However, comprehensive assessments of bolus
and basal insulin doses and macronutrient intake and their associa-
tions with glycaemia over the entire course of a multiple-stage cycle
race are lacking. The aim of the present study, therefore, was to char-
acterize insulin therapy, macronutrient intake and glycaemia in profes-
sional cyclists with T1D over a 5-day Union Cycliste Internationale
(UCI) road-cycle race.
2 | MATERIALS AND METHODS
This study was a prospective observational analysis of data collated
over 5 days of road-cycle racing. The study protocol was registered at
the German Clinical Trials Register (DRKS.de; DRKS00019928). The
study protocol was approved by the College of Engineering Ethics
Panel, Research Governance Swansea University, UK (2019–032), and
performed in line with Good Clinical Practice guidelines and the Dec-
laration of Helsinki. All participants gave their written informed con-
sent in advance of any trial-related activities.
2.1 | Eligibility criteria
Participants met the following inclusion criteria: diagnosis of T1D
≥12 months ago; age 18 to 65 years; and use of multiple daily injec-
tions (MDI) of insulin for 12 months or more as standard therapy. The
main exclusion criteria were: presence of a life-threatening disease;
proliferative retinopathy or maculopathy; severe neuropathy; recur-
rent severe hypoglycaemia (more than one severe hypoglycaemic
event during the previous 12 months); hypoglycaemia unawareness as
judged by the investigator; hospitalization for diabetic ketoacidosis
during the previous 6 months; and any other condition that would
interfere with trial participation or evaluation of results, as judged by
the investigator.
2.2 | Preparation in advance of the UCI tour
Prior to the racing season, participants performed a maximum cardio-
pulmonary exercise (CPX) test for the assessment of the aerobic,
anaerobic and maximum exercise capacity, conducted by the research
team and the Team Novo Nordisk staff.24 These CPX results were
used to describe the individual race intensity over the five stages of
the tour. The athletes were using an rtCGM device (Dexcom G6;
Dexcom Inc., San Diego, California) as their standard glucose mea-
surement device prior to enrolment in the study. The athletes wore
the glucose sensor at the back of the upper arm or at the hip. One
case was reported in which the sensor was changed during the 5-day
period. One day prior to the start of the race, the cyclists received
smart insulin pens (InPen; Companion Medical, San Diego, California)
to assess their insulin doses.25 Insulin doses were downloaded from
the smart insulin pens via a mobile phone (Bluetooth), and the type,
amount, and time point of insulin dosing was recorded. Priming doses
of insulin were automatically detected by the software, however, this
was also evaluated by the research team. On an individual basis, some
athletes might have been tapering and/or carbohydrate loading prior
the race period; however, this was not assessed in detail for the pur-
pose of this study.
2.3 | Five-day race period
From the start of the first race until the end of the last race, rtCGM
data, bolus and basal insulin doses and macronutrient intake were col-
lected. rtCGM data and insulin doses were downloaded from the
receiver device/smart insulin pen after the last race. Mealtime macro-
nutrient intake outside of the in-race phase was recorded by the
research team. Riders also provided descriptive and photographic
accounts of each meal, alongside information on any additional snacks
taken outside of set eating times. In-race macronutrient intake was
calculated according to the difference in the quantity of pre-race ver-
sus post-race food/drink package, with subsequent verification from
riders. Additional macronutrient intake received from the Team Novo
Nordisk support car was recorded by the research team.
2.4 | Statistical analyses
Data were analysed for normal distribution using a Shapiro–Wilk test
and are shown as mean ± SD or median (interquartile range) if applica-
ble. Glycaemia between the 2 days prior to the tour (lower amount of
training) versus the 5-day race period was assessed by paired t-test or
Wilcoxon test. Glycaemia, insulin doses and macronutrient intake
were analysed via repeated measures one-way ANOVA or Friedman
test with Holm–Sidak's or Dunn's multiple comparison test over the
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5 days of the race. Associations for glycaemia were evaluated by
means of linear regression modelling, with log-transformation if
required (P ≤ 0.05). All analyses were conducted using an intention-
to-treat approach. Sensor glucose data obtained from rtCGM were
stratified for time below range level 2 (TBR 2; <3.0 mmol/L
[<54 mg/dL]), time below range level 1 (TBR 1; 3.0–3.8 mmol/L
F IGURE 1 Comparison of glycaemic ranges for the pre-race period vs. 5-day race period for overall data (A) and stratified for daytime (B) and
night-time (C). TAR 1, time above range level 1; TAR 2, time above range level 2; TBR 1, time below range level 1; TBR, 2, time below range level
2; TIR, time in range. No significant differences were found for the comparisons (P > 0.05)
TABLE 1 Assessment of glycaemic
ranges over the overall 5-day race period,
and stratified by daytime and night-time
period
% of total time Day 1 Day 2 Day 3 Day 4 Day 5 P
TBR 2
Overall
0 (0–2) 0 (0–0) 0 (0–1) 0 (0–1) 0 (0–3) 0.81
TBR 2
Day
0 (0–2) 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0) 0.61
TBR 2
Night
N/Aa 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0.71
TBR 1
Overall
0 (0–9) 0 (0–12) 4 ± 3 0 (0–19) 5 (0–8) 0.72
TBR 1
Day
0 (0–9) 0 (0–3) 0 (0–3) 0 (0–19) 0 (0–3) 0.94
TBR 1
Night
N/A* 0 (0–29) 0 (0–17) 0 (0–0) 0 (0–18) 0.39
TIR
Overall
69 ± 15 72 ± 18 74 ± 17 74 ± 16 84 ± 14 0.67
TIR
Day
69 ± 15 72 ± 15 73 ± 16 80 ± 12 88 (66–94) 0.75
TIR
Night
N/Aa 72 ± 30 77 (65–100) 69 (32–100) 82 ± 22 0.53
TAR 1
Overall
16 ± 15 20 ± 15 19 ± 12 14 ± 10 9 (0–11) 0.29
TAR 1
Day
16 ± 15 23 ± 14 21 ± 10 14 ± 12 10 ± 11 0.32
TAR 1
Night
N/Aa 14 (0–38) 15 (0–14) 16 (0–40) 3 (0–0) 0.86
TAR 2
Overall
4 (0–23) 0 (0–4) 0 (0–7) 0 (0–6) 0 (0–0) 0.09
TAR 2
Day
4 (0–23) 0 (0–3) 0 (0–9) 0 (0–0) 0 (0–0) 0.07
TAR 2
Night
N/Aa 0 (0–0) 0 (0–0) 0 (0–22) 0 (0–0) 0.14
Abbreviations: N/A, not applicable; TAR 1/TAR 2, time above range level 1/level 2; TBR 1/TBR 2, time below range level 1/level 2; TIR, time in range.
aData are mean ± SD or median (interquartile range). Glycaemic ranges night-time day 1 were not
available since assessment of data started with the first day in-ride period. Data analysis started with the in-race period on day 1 until the end of the
in-race period on day 5.
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[54–69 mg/dL]), time in range (TIR; 3.9–10.0 mmol/L [70–180 mg/
dL]), time above range level 1 (TAR 1; >10.0–13.9 mmol/L
[>180–250 mg/dL]) and time above range level 2 (TAR 2;
>13.9 mmol/L [>250 mg/dL]).26 Data were also stratified for day-
time (6:00 AM to midnight) and night-time periods (12:01 AM to 5:59
AM). Glycaemic variability was calculated based on the coefficient of
variation in sensor glucose data.
3 | RESULTS
Seven professional cyclists with T1D with a mean ± SD age of
28 ± 4 years, body mass index of 20.9 ± 0.9 kg/m2, glycated
haemoglobin concentration of 56 ± 7 mmol/mol (7.3% ± 0.6%), dia-
betes duration of 10 ± 6 years, who were using MDI and had peak
oxygen uptake of 72 ± 5 mL/kg/min, were included in the study.
Three athletes were using insulin detemir (Levemir; Novo Nordisk
A/S, Bagsværd, Denmark), three were using insulin glargine U-100
(Lantus; Sanofi, Paris, France) and one insulin glargine U-300
(Toujeo; Sanofi) as basal insulin. Six athletes were using faster insulin
aspart (Fiasp; Novo Nordisk A/S) and one was using insulin Aspart
(Novo Rapid; Novo Nordisk A/S).
3.1 | Pre-race versus 5-day race-period glycaemia
When comparing the pre-race (−2 days) versus the 5-day race periods,
significant differences were only found in the coefficient of variation in
glycaemia (pre-race 30% ± 5% vs. 5-day race period 35% ± 9%; P = 0.03).
No significant differences were observed for the mean sensor glucose
levels (pre-race 8.5 ± 2.0 mmol/L [154 ± 26 mg/dL] vs. 5-day race period
7.9 ± 0.9 mmol/L [142 ± 16 mg/dL]; P = 0.12). When mean sensor
F IGURE 2 Violin plots for the
assessment of in-ride glycaemic ranges.
(A) Time below range level 1 (TBR 1;
P = 0.41). (B) Time in range (TIR; P = 0.42).
(C) Time above range level 1 (TAR 1;
P = 0.47). (D) Time above range level
2 (TAR 2; P = 0.23). TBR 2 is not shown
since the athletes did not spend any time
in this range
F IGURE 3 Comparison of (A) bolus
and (B) basal insulin doses over the
course of the 5 days. Values are given as
violin plots. *indicates statistical
significance. D, day
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glucose levels were stratified for time of day, a significant difference was
found for the night-time period (pre-race 8.3 ± 1.4 mmol/L
[150 ± 25 mg/dL] vs. 5-day race period 7.2 ± 1.7 mmol/L [129 ± 31 mg/
dL]; P = 0.04), while no significant difference was observed for the day-
time period (pre-race 8.7 ± 1.7 mmol/L [156 ± 31 mg/dL] vs. 5-day race
period 8.2 ± 0.8 mmol/L [147 ± 15 mg/dL]; P = 0.26). No significant
TABLE 2 Macronutrient intake over the 5-day period
Day 1 Day 2 Day 3 Day 4 Day 5 P
Overall,
kcal
3329 ± 268 3055 ± 420 3896 ± 611 3313 ± 811 3866 ± 1034 0.06
Overall
CHO, g
508 ± 42 439 (422–580) 579 ± 133 529 ± 130 498 ± 110 0.24
Overall
fat, g
73 ± 20 56 ± 5 91 ± 19 77
(33–81)
139 ± 57 0.01
Overall
protein, g
160 ± 19 165 (124–172) 194 ± 30 159 ± 29 131 (125–167) 0.08
Breakfast,
kcal
819 ± 150 773 ± 87 975 ± 226 998 ± 308 905 ± 275 0.11
Breakfast
CHO, g
131 ± 15 122 ± 22 157 ± 50 158 ± 45 128 ± 44 0.12
Breakfast
fat, g
20 ± 11 19 ± 6 24 ± 11 24 ± 15 28 ± 16 0.39
Breakfast
protein, g
30 ± 6 29 ± 4 34 ± 3 37 ± 12 36 ± 11 0.24
Pre-race snack,
kcal
0
(0–89)
60
(0–228)
0
(0–120)
0
(0–30)
126 ± 116 0.20
Pre-race snack
CHO, g
0
(0–18)
18 ± 22 0
(0–25)
0
(0–5)
24 ± 24 0.29
Pre-race snack
fat, g
0
(0–2)
3 ± 3 0
(0–2)
0
(0–1)
3 ± 3 0.52
Pre-race snack
protein, g
0
(0–1)
1
(0–2)
0 ± 0 0
(0–3)
2 ± 2 0.07
In-race
kcal
878 ± 226 778 ± 235 1016 ± 368 950 ± 559 817 ± 410 0.39
In-race
CHO, g
177 ± 45 159 ± 53 207 ± 89 195 ± 97 162 ± 69 0.33
In-race
fat, g
16 ± 6 12 ± 5 17 ± 9 6
(4–33)
8
(4–29)
0.65
In-race
protein, g
7 ± 4 6 ± 5 8 ± 5 8 ± 5 6 ± 6 0.70
Post-race snack,
kcal
569 ± 0 571 ± 102 702 (702–728) 576 (576–651) 190
(0–811)
0.07
Post-race snack
CHO, g
66 ± 0 72 ± 27 48
(48–55)
65
(65–82)
16
(0–91)
0.25
Post-race snack
fat, g
5 ± 0 9 ± 2 18 ± 0 7 ± 0 10 ± 11 0.06
Post-race snack
protein, g
64 ± 0 61
(49–62)
88
(88–88)
64
(64–65)
4
(0–79)
0.00
Dinner
kcal
1003 ± 230 801 ± 119 1079 ± 275 836 (606–929) 2016 (1202–2016) 0.02
Dinner
CHO, g
122 ± 24 108 ± 18 145 ± 18 102 ± 60 166 (115–166) 0.21
Dinner
fat, g
30 ± 11 14 ± 5 29 ± 18 16 ± 11 110 (47–110) 0.00
Dinner protein, g 59 ± 17 59 ± 16 59 ± 26 50 ± 27 86
(66–86)
0.46
Abbreviation: CHO, carbohydrates. Data are mean ± SD or median (interquartile range).
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differences were seen when overall glycaemic ranges were compared
(P > 0.05; Figure 1).
3.2 | Glycaemia over the 5-day race period
Over the course of the 5-day race period, no significant differences
were found for overall glycaemic variability (P = 0.75) or mean sensor
glucose levels (P = 0.16). No significant differences were found when
data were stratified for daytime (P = 0.14) and night-time glycaemic
viability (P = 0.09) or daytime (P = 0.33) and night-time (P = 0.18)
mean sensor glucose levels.
When data were assessed for glycaemic ranges, no significant dif-
ferences were found for TBR 2, TBR 1, TIR, TAR 1 and TAR 2 over
the course of the 5-day race period, or when data were stratified for
time of day (P > 0.05; Table 1).
3.3 | In-ride glycaemia
When comparing in-ride mean glucose levels (P = 0.34) and glycaemic
variability (P = 0.23) over the five stages, no significant differences
were found. Overall, no significant differences were found for any of
the glycaemic ranges (P > 0.05; Figure 2).
3.4 | Insulin administration
In-ride bolus insulin administration was uncommon and data were
only available for four athletes (mean ± SD bolus insulin dose for all
in-ride periods 5 ± 2 IU). Basal insulin dose was not adjusted over the
course of the 5 days (P = 0.64), but bolus insulin dose per hour was
altered (P = 0.03; Figure 3).
3.5 | Macronutrient intake
Significant differences were found over the course of the 5 days for
fat intake (P = 0.01). No significant differences were found for carbo-
hydrate (P = 0.24) and protein intake (P = 0.08). In-race intake of fat
(P = 0.65), carbohydrates (P = 0.33) and protein (P = 0.70) were not
significantly different (Table 2).
3.6 | Effects of exercise intensity and duration on
glycaemia and therapy
The overall absolute mean race intensity was 209 ± 17 W,
corresponding to 63% ± 5% of the anaerobic threshold (lactate turn
point 2 [LTP2]).
27 Stratified per day, race intensities were 188 ± 16 W
(58 ± 4% LTP2) on day 1, 211 ± 16 W (63 ± 3% LTP2) on day
2, 201 ± 14 W (62 ± 5% LTP2) on day 3, 234 ± 15 W (71 ± 6% LTP2)
on day 4 and 214 ± 40 W (63 ± 7% LTP2) on day 5. A higher mean
previous-day race intensity was associated with a lower mean sensor
glucose level (P = 0.03), less TAR 2 (P = 0.05) and lower doses of bolus
insulin administration (P = 0.04). No significant associations were
found for any other glycaemic range or glycaemic variability
(P > 0.05). A longer previous-day race duration was associated with
more TAR 2 (P = 0.05) and higher doses of basal insulin (P = 0.04). No
significant associations were found for any other glycaemic range,
mean sensor glucose levels or glycaemic variability (P > 0.05).
Previous-day race intensity and duration were not significantly associ-
ated with macronutrient intake (P > 0.05).
4 | DISCUSSION
This is the first study showing that professional cyclists with T1D
reduced their bolus insulin dose over the course of a 5-day race while
macronutrient intake as well as basal insulin dose remained
unchanged. In a recent descriptive report, it was shown that athletes
with T1D face a higher risk of hypoglycaemia during the nocturnal
period,23 but that these hypoglycaemic episodes were above that
deemed clinically relevant26; however, due to issues in data quality,
insulin therapy interpretation was unavailable. Our findings demon-
strate that professional cyclists with T1D reduce their total daily bolus
insulin dose while keeping carbohydrate intake consistent. Of note,
basal insulin dose was unaltered, which probably reflects the high
training workload of athletes, which does not differ much from race
conditions. It can be speculated that a carry-over effect might exist
with respect to basal insulin administration around the races. This
finding is contrary to that of a recent study, which showed that people
with T1D reduced their basal insulin dose/basal insulin rate around a
running event.28 However, that study was performed in recreationally
active people with T1D and the TIR was much lower (40%) than
observed in the present study. In another study it was found that high
intermittent carbohydrate intake during prolonged exercise, combined
with proactive use of rtCGM, was linked to good glycaemia during
prolonged exercise in recreationally active people with T1D.29 Never-
theless, the authors concluded that during pre-exercise/pre-competi-
tion carbohydrate loading, insulin doses should not be drastically
increased to avoid an increase in the time spent in hypoglycaemia.
Furthermore, since the athletes in the present study were using MDI
therapy, insulin adaptations around exercise and competition might
be different for athletes using CSII therapy.19,30 Previous studies
showed that reducing the basal rate by up to 80% 90 minutes prior
the onset of exercise is suitable to improve glycaemia and lower the
risk of hypoglycaemia,10,31 but detailed research around competitions
and CSII is missing. Although previous studies have shown that basal
insulin dose reduction can increase TIR16 for training over consecutive
days and lower the risk of nocturnal hypoglycaemia,32 the Team Novo
Nordisk athletes favour an alternative approach, in which the empha-
sis is placed on making modifications to the bolus insulin to carbohy-
drate rate. This finding supports the established advantages of extra
carbohydrates12 and/or bolus insulin dose reductions14 in avoiding
exercise-induced hypoglycaemia and improving overall glycaemia
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during exercise.13 Furthermore, reducing the bolus insulin dose and/or
consuming extra carbohydrates might also be easier when compared
to basal insulin reductions for recreationally active people with T1D
using MDI therapy, and rather allow spontaneous exercise. Neverthe-
less, the decision for a therapy strategy around exercise/competition
should be individualized based on several factors such as experience
with exercise, risk of dysglycaemia and volume, type and mode of
exercise. The clinical concerns associated with hypoglycaemia during
exercise are detrimental to both physical (reduced power output) and
psychological (increased worry and anxiety) aspects of exercise per-
formance in people with T1D.33 Thus, the avoidance of
hypoglycaemia during exercise is an integral component of optimizing
race performance in elite athletes with T1D.
In a recent study assessing glycaemic responses to exercise train-
ing in professional cyclists with T1D, previous-day exercise intensity
was not associated with next-day glycaemia.24 Physiological and psy-
chological stress might be much higher around racing conditions,
which might explain the divergent results in comparisons of training
camp versus racing. However, in the two existing studies that have
investigated this group of athletes,23,24 detailed information on insulin
administration was missing.
When assessing glycaemia in comparison to non-race conditions,
only glycaemic variability deteriorated. This finding is in slight contrast
to a previous study,28 in which glycaemic variability decreased during
a running competition when compared to the pre-competition period
in recreationally active people with T1D. When data were stratified
for time of day, night-time mean sensor glucose improved during the
5-day race period when compared to pre-race conditions, which is in
contrast to previous studies where glycaemia in general
deteriorated.23,24
In-race glycaemia, as assessed via mean sensor glucose levels,
glycaemic ranges and glycaemic variability, was not affected by the
exercise accumulating effect (day 1 to day 5), a finding consistent with
previous studies.12,16 These results are in support of the effectiveness
of current glycaemic management strategies employed by the athletes
of the Team Novo Nordisk around a multiple-stage professional
cycling race. Interestingly, longer previous-day race durations were
accompanied by more TAR and higher doses of basal insulin. It is diffi-
cult to draw any conclusions from this finding; hence it could be inter-
preted as a random result.
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